Search clinical trials for: BU-Everolimus

Total 1000 results

Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC)

Germany
Umberto I Hospital, Frosinone Italy

Unknown

Study of ABSORB Stent in Acute Myocardial Infarction (ABSORB-ACS)

Acute Myocardial Infarction | Artery; Deformity, Coronary (Acquired)

Italy
KK Women's and Children's Hospital

Recruiting

The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial

Infertility | Male Infertility | Reproductive Issues | Traditional Chinese Medication (TCM)

Singapore
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Radboud University Medical Center
Novartis

Completed

Influence of Exceptional Patient Characteristics on Everolimus Exposure (INPRES)

Breast Neoplasms

Netherlands
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Yonsei University

Unknown

A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions

Coronary Artery Disease

Korea, Republic of
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
University of Chicago
Novartis Pharmaceuticals

Terminated

Everolimus Versus Placebo in Head and Neck Cancer

Head and Neck Cancer

United States
Yonsei University

Completed

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Head and Neck Cancer

Korea, Republic of
Institut National de la Santé Et de la Recherche...

Terminated

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Kaposi Sarcoma

France
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
Abbott Medical Devices

Completed

ABSORB II Randomized Controlled Trial (ABSORB II)

Coronary Artery Disease

Belgium
Ahmad Tarhini
Novartis Pharmaceuticals

Completed

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Seoul National University Hospital
Abbott

Unknown

Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE)

Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Percutaneous Coronary Intervention

Korea, Republic of
Novartis Pharmaceuticals

Completed

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Technical University of Munich

Terminated

Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Lymphoma

Germany
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

Belgium, Italy, Poland, Sweden, France
Abbott Medical Devices

Terminated

The ABSORB BTK (Below The Knee) Clinical Investigation

Atherosclerosis | Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Claudication | Critical Limb Ischemia | PAD | PVD | Lower Limb Disease | PAOD

Belgium
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
Seagen Inc.

Terminated

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
North Texas Veterans Healthcare System

Completed

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study (ACE-CTO)

Coronary Occlusions

United States
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Tuberous Sclerosis | Angiolipoma

United States
Samsung Medical Center

Completed

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

Korea, Republic of
Technical University of Munich

Completed

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Germany
Novartis Pharmaceuticals

No longer available

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Organ Transplantation

United States, Italy, Spain, United Kingdom, Germany, Taiwan, Belgium, Australia, Czechia, France, Switzerland, Norway, Canada, Brazil, Puerto Rico, Russian Federation, New Zealand, Poland, South Africa
University of Freiburg

Completed

Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents (EVERBIOII)

Coronary Artery Disease

Switzerland
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Acute Myeloid Leukemia
University of Cologne
Boehringer Ingelheim

Completed

BIBF 1120 and RAD001 in Solid Tumors - Phase I (BARIS)

Solid Tumors

Germany
Fudan University

Not yet recruiting

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma (ALTER-UC-001)

Renal Cell Carcinoma

China
University of California, San Francisco
Novartis; amfAR, The Foundation for AIDS Research

Completed

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant (HIVTR-EVE)

HIV | Liver Transplant | Kidney Transplant

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Prostate Cancer Patients With Detectable PSA Following Prostatectomy

United States
Novartis Pharmaceuticals

Completed

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (PILLAR2)

Diffuse Large B-cell Lymphoma

China, United States, Colombia, Turkey, Spain, Egypt, Canada, Italy, Singapore, Australia, Austria, Czechia, Greece, Israel, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Lebanon, Japan, Poland, Slovakia, Switzerland, G... and more
Flanders Medical Research Program

Completed

PREVENT: Promus BTK (PREVENT)

Peripheral Arterial Disease

Belgium, Germany, New Zealand
Universita di Verona

Completed

Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy (CART)

Cardiac Allograft Vasculopathy

Italy, Netherlands
Novartis Pharmaceuticals

Completed

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Advanced or Metastatic Pancreatic Adenocarcinoma

Germany
University Hospital, Basel, Switzerland

Completed

Open-label Study on Treatment of Primary Aldosteronism With Everolimus

Primary Aldosteronism

Switzerland
Novartis Pharmaceuticals

Completed

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Hodgkin Lymphoma

United States
Takeshi Morimoto

Completed

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial (NEXT)

Coronary Artery Disease

Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Malignant Mesothelioma

United States
Dana-Farber Cancer Institute
GlaxoSmithKline; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women...

Completed

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Kidney Cancer | Solid Tumor

United States
St. Joseph's Healthcare Hamilton
Novartis Pharmaceuticals; McMaster University

Completed

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Carcinoma, Renal Cell

Canada
Northern Hospital, Australia
Abbott Medical Devices

Unknown

Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms (APPOSE)

Coronary Artery Disease

Australia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

Kidney Transplantation

Belgium, Taiwan, Italy, Germany, Spain, Switzerland, Australia, Singapore, Norway, Netherlands, Colombia, Argentina, Brazil, Austria, Slovakia, France, Czech Republic

Search clinical trials for: BU-Everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations